NCT05890742 2024-03-15A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon CancerInnovent Biologics (Suzhou) Co. Ltd.Phase 3 Recruiting360 enrolled